SOUTH SAN FRANCISCO, Calif. — March 5, 2026 — Leads & Copy — Tenaya Therapeutics, Inc. (NASDAQ: TNYA) has entered into a research collaboration agreement with Alnylam Pharmaceuticals (Nasdaq: ALNY) to discover novel human genetic targets for potential treatments of cardiovascular diseases.
Tenaya will receive up to $10 million in upfront payments, research funding, and up to $1.13 billion in milestone payments.
Faraz Ali, Chief Executive Officer of Tenaya Therapeutics, said the collaboration underscores Tenaya’s commitment to rigorous science and capitalizes on proprietary capabilities. He added that by combining target identification and validation capabilities with Alnylam’s leadership in RNA interference therapeutics, there is an opportunity to advance candidates for novel genetic targets and create transformational medicines for patients with heart disease.
Under the agreement, Tenaya Therapeutics will validate up to 15 gene targets and receive up to $10 million upfront, plus reimbursement for related costs over the two-year validation term. Alnylam will handle all development and commercialization activities. Tenaya is eligible for up to $1.13 billion in development and commercial milestone payments from Alnylam if all novel genetic targets lead to approved therapeutics for cardiovascular disease.
Tenaya has a portfolio of integrated capabilities for target identification and validation anchored in human genetics. These capabilities include the use of human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) with high throughput in vitro screening, imaging analysis, and machine learning algorithms to identify novel genetic targets, and human engineered heart tissue and preclinical in vivo models of human disease to validate and characterize potential product candidates. The company’s capabilities have generated more than 150 genetic targets and contributed to the discovery and development of clinical-stage candidates, including the TN-201 and TN-401 gene therapies and TN-301 small molecule, as well as diverse early-stage programs.
Tenaya Therapeutics is focused on discovering, developing, and delivering therapies that address the underlying drivers of heart disease. The company’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), and TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Tenaya has a portfolio of medicines based on genetic insights, including TN-301, a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure and related cardio/muscular disease, and multiple early-stage programs in preclinical development aimed at the treatment of both rare genetic disorders and more prevalent heart conditions.
Source: Tenaya Therapeutics
